E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Recurrent malignant childhood central nervous system tumors |
Rezidivierte maligne ZNS-Tumoren des Kindes- und Jugendalters |
|
E.1.1.1 | Medical condition in easily understood language |
Recurrent malignant childhood central nervous system tumors |
Rezidivierte maligne ZNS-Tumoren des Kindes- und Jugendalters |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Measurement of CSF-levels of temozolomide in patients treated with temozolomide |
Messung der Konzentration von Temozolomid nach oraler Einnahme bei Kindern untschiedlichen Alters im Liquor |
|
E.2.2 | Secondary objectives of the trial |
Measurement of CSF-levels of temozolomide in patients treated with temozolomide |
Messung der Konzentration von Temozolomid nach oraler Einnahme bei Kindern untschiedlichen Alters im Liquor |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Female or male, aged between 0 and 19 years (at time of initial diagnosis) - Recurrent brain tumor with leptomeningeal dissemination or risk of leptomeningeal dissemination of any histology - Treatment with temozolomide for therapeutic reasons - Treatment with intrathecal administered chemotherapy for therapeutic reasons - Life expectancy of at least 8 weeks - Written informed consent of patients and/or parents - Serum creatinine < 1.5 mg/dL - Total serum bilirubin < 2.0 mg/dL and ALT less than 5 times upper limit of normal - Platelet count > 40.000/mm3 within 48 hours before intrathecal treatment
|
- männlich oder weiblich, Alter zwischen 0 und 19 Jahren (bei Diagnose) - Rezidivierter Hirntumor mit leptomeningealer Dissemination oder Risiko einer leptomeningealen Dissemination - Therapie mit Temozolomid aus therapeutischen Gründen - Therapie mit intraventrikulärer Chemotherapie aus therapeutischen Gründen - Lebenserwartung von zumindest 8 Wochen - Schriftliche Einverständniserklärung des Patienten / der Eltern - Serum-Kreatinin < 1,5 mg/dl - Serum-Bilirubin < 2,0 mg/dl, Transaminasen weniger als 5-fach über oberem Grenzwert - Thrombozyten > 40.000/nl |
|
E.4 | Principal exclusion criteria |
- Treatment with temozolomide not indicated - Intrathecal therapy not indicated - Evidence of obstructive hydrocephalus or compartmentalization of CSF flow - Severe uncontrolled infection - Pregnancy or breast feeding
|
- keine Therapie mit Temozolomid indiziert - keine Therapie mit intraventrikulärer Chemotherapie indiziert - unkontrollierte Infektion - Zeichen von obstruktivem Hydrocephalus - Schwangerschaft oder Stillen |
|
E.5 End points |
E.5.1 | Primary end point(s) |
CSF-levels of temozolomide identified |
Liquor-Spiegel von Temozolomid identifiziert |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
CSF-levels of temozolomide identified |
Liquor-Spiegel von Temozolomid identifiziert |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
Pharmacokinetic pilot study |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |